Shares of Ardelyx Inc. (NASDAQ:ARDX) rose 4.8% during trading on Wednesday . The stock traded as high as $11.99 and last traded at $11.97, with a volume of 176,948 shares changing hands. The stock had previously closed at $11.42.

ARDX has been the subject of several analyst reports. Zacks Investment Research raised Ardelyx from a “sell” rating to a “hold” rating in a research note on Wednesday, May 25th. Leerink Swann reiterated a “buy” rating on shares of Ardelyx in a research report on Thursday, June 23rd. Cantor Fitzgerald reiterated a “buy” rating on shares of Ardelyx in a research report on Wednesday, June 22nd. Wedbush reiterated an “outperform” rating and set a $24.00 target price on shares of Ardelyx in a research report on Thursday, June 23rd. Finally, Citigroup Inc. dropped their target price on Ardelyx from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $20.00.

The stock’s market cap is $565.58 million. The firm has a 50 day moving average price of $10.48 and a 200-day moving average price of $8.96.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/ardelyx-inc-ardx-stock-price-up-4-8.html

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.08. On average, equities analysts expect that Ardelyx Inc. will post ($3.03) earnings per share for the current year.

In other Ardelyx news, SVP Elizabeth A. Grammer sold 6,859 shares of the firm’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $11.21, for a total value of $76,889.39. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Nea 15 Gp, Llc bought 1,527,301 shares of the business’s stock in a transaction on Monday, July 18th. The stock was acquired at an average cost of $8.73 per share, for a total transaction of $13,333,337.73. The disclosure for this purchase can be found here. 15.46% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the company. Foresite Capital Management III LLC acquired a new position in shares of Ardelyx during the first quarter worth about $5,038,000. Deerfield Management Co. acquired a new position in shares of Ardelyx during the first quarter worth about $2,137,000. JPMorgan Chase & Co. boosted its position in shares of Ardelyx by 167.3% in the second quarter. JPMorgan Chase & Co. now owns 262,556 shares of the biopharmaceutical company’s stock worth $2,292,000 after buying an additional 164,314 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Ardelyx by 206.8% in the first quarter. Geode Capital Management LLC now owns 144,821 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 97,621 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Ardelyx by 44.2% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 311,165 shares of the biopharmaceutical company’s stock worth $2,418,000 after buying an additional 95,418 shares in the last quarter. 62.84% of the stock is currently owned by hedge funds and other institutional investors.

About Ardelyx

Ardelyx, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment.

5 Day Chart for NASDAQ:ARDX

Receive News & Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.